Overview

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.
Phase:
Phase 2
Details
Lead Sponsor:
Kala Pharmaceuticals, Inc.
Treatments:
Loteprednol Etabonate